Allogene Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALLO Nasdaq 2830 www.allogene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Allogene Therapeutics, Inc.

3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 - Dec 26th, 2024 6:07 pm
Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock? - Dec 26th, 2024 5:00 pm
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Dec 24th, 2024 12:47 pm
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Dec 16th, 2024 1:30 pm
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - Dec 12th, 2024 1:30 pm
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? - Dec 2nd, 2024 6:19 pm
Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why - Nov 25th, 2024 5:00 pm
Allogene Therapeutics Announces Participation in December Investor Conferences - Nov 19th, 2024 1:30 pm
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence - Nov 18th, 2024 1:30 pm
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - Nov 14th, 2024 3:24 pm
Allogene's Q3 Loss Narrower Than Expected, Sales Nil - Nov 8th, 2024 3:15 pm
Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ... - Nov 8th, 2024 11:07 am
Allogene Therapeutics: Q3 Earnings Snapshot - Nov 7th, 2024 9:11 pm
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update - Nov 7th, 2024 9:02 pm
CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up - Nov 7th, 2024 3:29 pm
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS - Nov 7th, 2024 3:00 pm
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting - Nov 5th, 2024 2:10 pm
Allogene Therapeutics Announces Participation in November Investor Conferences - Nov 4th, 2024 1:30 pm
Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline - Nov 1st, 2024 2:00 pm
Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know - Oct 31st, 2024 2:01 pm